ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Market Cap	26.72M -41.4%
Revenue (ttm)	24.25M +136.7%
Net Income	-35.91M
EPS	-1.51
Shares Out	23.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,211
Open	1.170
Previous Close	1.180
Day's Range	1.040 - 1.170
52-Week Range	1.040 - 22.850
Beta	2.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company’s lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patt...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 19
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EXPRS2

Financial Performance

In 2025, STO:EXPRS2's revenue was 12.21 million, an increase of 56.00% compared to the previous year's 7.83 million. Losses were -38.09 million, 5.68% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error